The glioblastoma initiative, supported by uMotif, is receiving fantastic feedback from patients and their caregivers as well as insights into what they expect from their care

uMotif adds the accomplished software leader behind some of the most successful patient engagement and clinical trial management platforms to our leadership team.

Report names uMotif as one of the 27 most promising HealthTech companies

We’re delighted to be providing our data capture platform to support this work

Rob Nichols, VP of Customer Experience, fresh from such a trip to Vienna, gives his view

Driving Real-World Research Through Patient-Centric Engagement

We're building the team to deliver next generation patient data capture platform for clinical research

OurBrainBank is created by, with and for patients with Glioblastoma - one of the most aggressive, complex and deadly forms of cancer.

We’re currently growing our engineering, sales and account delivery teams as we take our patient-centric approach to more clients and patients.

We're delighted to have been nominated as one of the world's leading digital health companies by the Journal of mHealth

A poster presentation at the BOPA conference in the UK shows successful deployment of uMotif at the Christie hospital

A paper published in JMIR demonstrates that uMotif is the most effective platform to engage patients in data capture for research

Hotwire featured an article on patient centricity by our CEO, Bruce Hellman

A peer-review published study has shown that patients who self-track their health have significantly better cancer outcomes and survival rates

A new patient-powered movement - Our Brain Bank - aims to move brain cancer from terminal to treatable, powered by patients using uMotif technology

Our cloud based data capture technology has been featured as a case study by Amazon Web Services, our hosting provider

We picked up another award at the AXA PPP HealthTech & You Awards, scooping the 'Professional's Choice' category for engaging patients in large-scale research projects

Our new partnership will provide clinical trial sponsors with patient-centric technology for trials of all phases, including Real-World Evidence.

The BBC World Service's programme 'World Hacks' covered the growing interest in patients donating their health data for research, focusing on the uMotif platform

The final patients have completed their 100 Days of tracking for 100 For Parkinson's, so we now have the final dataset containing over 2.2 million datapoints. The latest analyses are ...

uMotif has signed a partnership agreement with AstraZeneca, a top-10 global pharmaceutical company

uMotif in partnership with QuintilesIMS was chosen from dozens of responses to the ‘Pharma Challenge’, an invitation issued by the NHS Cancer Vanguard to the pharmaceutical and life sciences industry to help the NHS make better use of medicines and minimise waste.

A new study in Parkinson’s proves the value and clinical impact of patients using their own devices to capture and monitor symptoms and treatments.

Using the uMotif app during the Smart PD trial, Sam was able to get a better understanding of her Parkinson's

​Global Kinetics Corporation and uMotif have announced a new partnership to offer a comprehensive, validated and simple to use data capture platform to advance the treatment and understanding of Parkinson's disease.

Watch the latest video, where one of the participants from our observational study describes his experience using the uMotif app

Our collaboration with the University of Manchester is featured on the FRONT PAGE of the Daily Express today - describing the preliminary findings that the weather may.....

Our ground-breaking study in partnership with The Cure Parkinson’s Trust, Parkinson’s UK and the European Parkinson’s Disease Association is entering the last two weeks of recruitment. There’s still time for people with Parkinson’s and healthy volunteers to join over 4000 others and track their health for 100 days using their own smartphone or tablet.

umotif has been named as one of the South East's most visionary digital companies in the inaugural 'Digital Innovators Power List' launched today by international law firm Bird & Bird LLP and London-based news brand, City A.M.

 One person in every 500 has Parkinson’s disease, with more than 127,000 people in the UK and around 10 million people globally diagnosed with the condition.  A unique global health project – 100 for Parkinson’s - has engaged thousands of people across the world to track their health, using smartphone technology, to provide valuable new insights on the impact of Parkinson’s on their daily lives.   With over 4,000 participants and millions of data points captured, the study is now the world’s largest of its type in Parkinson’s, capturing more high quality health data from more patients over a longer period of time.

World Parkinson's Congress is ending today in Portland, so we've published some more data from 100 For Parkinson's on Mood, Sleep and Stress levels of those with and without Parkinson's...

​Preliminary results, national media coverage and another 2,500 participants: It's been another couple of eventful weeks for the ground-breaking Cloudy with a Chance of Pain study

We're delighted to be working in partnership with the Picker Institute – the leading charity improving healthcare through measurement of experience.

​We launched our global 100 for Parkinson's study at the start of 2016, and have had an incredible response.

u​Motif CEO Bruce Hellman wrote an article in the Guardian on the future of technology in healthcare.

A year ago the uMotif team started working with the IDEO London team, as part of their incredible Startup In Residence Programme.